The US Food and Drug Administration (FDA) has approved latanoprostophthalmic emulsion 0.005% (Xelpros, Sun Pharmaceuticals) to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, the company has announced.
Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations, the company said.
For more information: https://www.medscape.com